NCT00971880|Completed
Loading search results
Sponsor study identifier
observational
100
1 country
1
Study Start
May 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2010
Actual (reported)Study Completion
November 2010
Actual (reported)Patients suffering from Thalassemia or another hemoglobinopathies required regular blood transfusions. The complications and adverse effects of blood transfusions can be classified as immediate and late. Among the immediate effects the most common are allergic reactions and fever, besides congestive heart failure in patients with cardiomyopathy. The late effects are mostly related to blood transmitted infections like HIV or Hepatitis C infections. The purpose of this study is to summarize the data of those complications in a cohort of 100 patients receiving regular blood transfusion.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2009
Date type not reportedThis date has not been verified as actual or estimated.
September 3, 2009
Actual (reported)September 4, 2009
Actual (reported)November 2010
Actual (reported)November 2010
Actual (reported)All the patients with blood disorders that require blood transfusions
Summary of immediate and late adverse effects of blood transfusions
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients receiving blood transfusions due to chronic hematologic disorders
Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center
Afula, 18101, Israel
First Submitted
September 3, 2009
First Posted
September 4, 2009
Study Start
May 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
November 2010
Bone Marrow for Hemoglobinopathy Research
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
Contact the study team to confirm eligibility.
Study Completion
November 2010
Actual (reported)Last Updated
August 26, 2011
Record last verified: 2011-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: